1. Home
  2. ANAB vs XYF Comparison

ANAB vs XYF Comparison

Compare ANAB & XYF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • XYF
  • Stock Information
  • Founded
  • ANAB 2005
  • XYF 2014
  • Country
  • ANAB United States
  • XYF China
  • Employees
  • ANAB N/A
  • XYF N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • XYF Finance: Consumer Services
  • Sector
  • ANAB Health Care
  • XYF Finance
  • Exchange
  • ANAB Nasdaq
  • XYF Nasdaq
  • Market Cap
  • ANAB 621.1M
  • XYF 708.7M
  • IPO Year
  • ANAB 2017
  • XYF 2018
  • Fundamental
  • Price
  • ANAB $20.14
  • XYF $13.44
  • Analyst Decision
  • ANAB Buy
  • XYF
  • Analyst Count
  • ANAB 10
  • XYF 0
  • Target Price
  • ANAB $48.00
  • XYF N/A
  • AVG Volume (30 Days)
  • ANAB 500.2K
  • XYF 536.3K
  • Earning Date
  • ANAB 08-06-2025
  • XYF 08-18-2025
  • Dividend Yield
  • ANAB N/A
  • XYF 3.74%
  • EPS Growth
  • ANAB N/A
  • XYF 32.83
  • EPS
  • ANAB N/A
  • XYF 4.76
  • Revenue
  • ANAB $123,164,000.00
  • XYF $909,710,294.00
  • Revenue This Year
  • ANAB N/A
  • XYF N/A
  • Revenue Next Year
  • ANAB $24.39
  • XYF N/A
  • P/E Ratio
  • ANAB N/A
  • XYF $2.94
  • Revenue Growth
  • ANAB 304.17
  • XYF 31.55
  • 52 Week Low
  • ANAB $12.21
  • XYF $4.22
  • 52 Week High
  • ANAB $40.70
  • XYF $20.36
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 31.39
  • XYF 34.03
  • Support Level
  • ANAB $19.55
  • XYF $13.31
  • Resistance Level
  • ANAB $22.03
  • XYF $14.64
  • Average True Range (ATR)
  • ANAB 1.50
  • XYF 0.77
  • MACD
  • ANAB -0.53
  • XYF 0.02
  • Stochastic Oscillator
  • ANAB 12.05
  • XYF 15.58

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About XYF X Financial each representing six

X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.

Share on Social Networks: